A Look at U.S. Arms Sales to Middle East, & More from CRS
Some restrictions on U.S. arms sales to human rights violators in the Middle East have recently been relaxed by the Trump Administration, a new report from the Congressional Research Service noted.
“In early 2016, Bahrain submitted a request to purchase a number of F-16s [from the U.S.] and to upgrade its existing aircraft in a deal worth as much as $4 billion. However, when the Obama Administration informally pre-notified the sale to Congress, it explained that the sale would not move forward unless Bahrain took steps toward improving its record on human rights. The Trump Administration dropped those conditions in March 2017, even though U.N. investigators have asserted a ‘sharp deterioration’ of human rights over the past year in Bahrain. Congress was formally notified of the sale in September 2017.”
The use of self-imposed U.S. restriction on arms sales “as a mechanism to achieve changes in [foreign] behavior has questionable effectiveness and can have unintended consequences,” said CENTCOM Commander Gen. Joseph L. Votel in Senate testimony quoted by CRS. “We should avoid using the programs as a lever of influence or denial to our own detriment.”
The new CRS report describes and analyzes arms sales to seven Middle Eastern countries.
“The United States is the single largest arms supplier to the Middle East and has been for decades. However, other major producers like Russia, France, and China are also key players in the region. Their respective strategies and goals for arms sales appear to differ in some ways,” the report said.
See Arms Sales in the Middle East: Trends and Analytical Perspectives for U.S. Policy, October 11, 2017.
Other new and updated reports from the Congressional Research Service include the following.
The Committee on Foreign Investment in the United States (CFIUS), updated October 11, 2017
NAFTA Renegotiation and Modernization, October 12, 2017
Defense Primer: Military Pay Raise, CRS In Focus, updated October 10, 2017
The Army’s Warfighter Information Network-Tactical (WIN-T) Program, CRS Insight, October 10, 2017
U.S. Periods of War and Dates of Recent Conflicts, updated October 11, 2017
Instances of Use of United States Armed Forces Abroad, 1798-2017, updated October 12, 2017
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.
Called today to speak on behalf of U.S. science and technology, Dr. Jedidah Isler, astrophysicist, educator, strategist, policy-maker, and science communicator, will provide constructive, nonpartisan feedback to the House Committee’s hearing “American Global Competitiveness at 250: Legislative Proposals to Secure U.S. Technology Leadership.”
“Federal data and access to it is not a partisan issue. It is a people issue. Our country cannot achieve greatness without access to the data that measure what we value, who we are, and where we’re heading.”
The United States’ biosecurity governance system is structurally incapable of detecting and responding to certain classes of threats. U.S. biosecurity tools have not kept pace with technological advancements or a changing threat landscape.